6533b829fe1ef96bd128a489
RESEARCH PRODUCT
Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
Pe PensonE BruckertD MaraisŽ ReinerM PirroA SahebkarG BajraktariE MirrakhimovM RizzoDp MikhailidisA SachinidisD GaitaG LatkovskisM MazidiPp TothD PellaF AlnouriA PostadzhiyanH YehGbj ManciniS HaehlingM BanachJ AcostaM Al‐khnifsawiF AlnouriF AmarAg AtanasovG BajraktariM BanachS BhaskarI BytyçiB BjelakovicE BruckertA CafferataR CeskaAfg CiceroX ColletM DaccordO DescampsD DjuricR DurstMv EzhovZ FrasD GaitaAv HernandezSr JonesJ JozwiakN KakauridzeA KallelN KatsikiA KheraK KostnerR KubiliusG LatkovskisGbj ManciniAd MaraisSs MartinJa MartinezM MazidiDp MikhailidisE MirrakhimovAr MiserezO MitchenkoNp MitkovskayaPm MoriartySm NabaviD NairDb PanagiotakosG ParaghD PellaPe PensonZ PetrulionieneM PirroA PostadzhiyanR PuriA RedaŽ ReinerD RadenkovicM RakowskiJ RiadhD RichterM RizzoM RuscicaA SahebkarN SattarM SerbanAma ShehabAb ShekCr SirtoriC StefanuttiT TomasikPp TothM ViigimaaP ValdivielsoD VinereanuB VohnoutS HaehlingM VrablikNd WongH YehJ ZhishengA Zirliksubject
KardiologiDrucebo effect Nocebo effect SAMS Statin intoleranceMusclesSAMSNocebo effectLipidsQPRSStatin intolerance.Muscular DiseasesStatin intolerancePhysiology (medical)Drucebo effectHumansOrthopedics and Sports MedicineCardiac and Cardiovascular SystemsHydroxymethylglutaryl-CoA Reductase Inhibitorsdrucebo effect ; nocebo effect ; SAMS ; statin intolerancedescription
Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-01-01 | Journal of Cachexia Sarcopenia and Muscle |